NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site

Countries: China

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥18 years, at the time of signing the informed consent.
* ECOG performance status 0-2.
* Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.

Exclusion Criteria:

* Be participating in other intervention clinical trials.
* Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
* Previous enrolment in the other QIP study.

Locations (46)

Anning, China
Anqing, China
Changzhi, China
Daqing, China
Dazhou, China
Dazhu, China
Dingzhou, China
Ganzhou, China
Guangzhou, China
Guang’an, China
Hanzhong, China
Hebi, China
Hengyang, China
Huaibei, China
Jining, China
Jinzhou, China
Liyang, China
Lu'an, China
Meihekou, China
Nanchong, China
Nanyang, China
Ningde, China
Ningxiang, China
Panjin, China
Pingxiang, China
Quanzhou, China
Shengzhou, China
Suzhou, China
Taizhou, China
Tancheng, China
+ 16 more on CT.gov